Allogene Therapeutics Announces Proposed Public Offering of Common Stock and Suspends ATM Program

On April 13, 2026, Allogene Therapeutics, Inc. announced the commencement of a proposed underwritten public offering of its common stock. In conjunction with this new offering, the company has suspended its existing 'at-the-market' (ATM) equity facility. Specifically, it has halted the offering of any shares under the sales agreement prospectus dated April 25, 2024, which was part of a Sales Agreement originally entered into on November 5, 2019, with TD Securities (U.S.A.) LLC (formerly Cowen and Company, LLC). Allogene stated it will not make further sales under the existing Sales Agreement until a new prospectus or prospectus supplement is filed with the SEC. The filing does not disclose the intended size or pricing of the proposed underwritten offering. This move typically indicates a transition from opportunistic ATM sales to a structured capital raise to fund ongoing operations and clinical development programs.